Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Perspective Therapeutics (CATX) Non Operating Income (2016 - 2026)

Perspective Therapeutics' Non Operating Income history spans 17 years, with the latest figure at $2.1 million for Q1 2026.

  • On a quarterly basis, Non Operating Income fell 42.76% to $2.1 million in Q1 2026 year-over-year; TTM through Mar 2026 was $7.6 million, a 41.45% decrease, with the full-year FY2025 number at $9.1 million, down 12.65% from a year prior.
  • Non Operating Income hit $2.1 million in Q1 2026 for Perspective Therapeutics, up from $1.5 million in the prior quarter.
  • Over the last five years, Non Operating Income for CATX hit a ceiling of $3.7 million in Q1 2025 and a floor of $28000.0 in Q2 2022.
  • Historically, Non Operating Income has averaged $1.4 million across 5 years, with a median of $1.2 million in 2024.
  • Biggest five-year swings in Non Operating Income: tumbled 94.12% in 2023 and later skyrocketed 8136.36% in 2024.
  • Tracing CATX's Non Operating Income over 5 years: stood at $561000.0 in 2022, then tumbled by 94.12% to $33000.0 in 2023, then skyrocketed by 8136.36% to $2.7 million in 2024, then tumbled by 43.01% to $1.5 million in 2025, then soared by 35.05% to $2.1 million in 2026.
  • Business Quant data shows Non Operating Income for CATX at $2.1 million in Q1 2026, $1.5 million in Q4 2025, and $1.9 million in Q3 2025.